Literature DB >> 17636607

Ovulation suppression for endometriosis.

E Hughes1, J Brown, J J Collins, C Farquhar, D M Fedorkow, P Vandekerckhove.   

Abstract

BACKGROUND: Endometriosis is the finding of endometrial glands or stroma in sites other than the uterine cavity. Endometriosis appears to be an oestrogen dependent condition. This hormonal dependency has prompted the therapeutic use of ovulation suppression agents, in an effort to improve subsequent fertility.
OBJECTIVES: To assess the effectiveness of ovulation suppression agents, including danazol, progestins and oral contraceptives, in the treatment of endometriosis-associated subfertility in improving pregnancy outcomes including live birth. SEARCH STRATEGY: We searched the Cochrane Menstrual Disorders and Sub-fertility Group's specialised register of trials (searched October 5th, 2007) the Cochrane Register of Controlled Trials (The Cochrane Library, Issue 3, 2007), MEDLINE (1966-October 2007), EMBASE (1980 - October 2007) and reference lists of articles. SELECTION CRITERIA: Randomised trials comparing an ovulation suppression agent with placebo or no treatment, or a suppressive agent with danazol or a GnRH with oral contraception in women with endometriosis. A total of twenty three RCTs comparing an ovulation suppression agent with placebo or no treatment, or a suppressive agent with danazol or a GnRH with oral contraception were identified. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data and assessed quality. We contacted study authors for additional information. Quality was assessed by of method of randomization,allocation concealment, blinding, completeness of follow-up, presence or absence of crossover and co-intervention. 2 x 2 tables were generated for all relevant outcomes. Odds ratios were generated using the Peto modified Mantel-Haenszel technique. Statistical heterogeneity was assessed using the I(2) test of heterogeneity. Subgroup analysis was conducted on those couples clearly identifiable as infertile or wanting to conceive. MAIN
RESULTS: Twenty four trials were included. The odds ratio for pregnancy following ovulation suppression versus placebo or no treatment for all women randomised was 0.79 (95% CI 0.54 to 1.14), P = 0.21 and 0.80 (95% CI 0.51 to 1.24), P = 0.32 respectively for subfertile couples only despite the use of a variety of suppression agents. There was no evidence of benefit from the treatment. The common odds ratio for pregnancy following all agents versus danazol for all women randomised was 1.38 (95% CI 1.05 to 1.82), P = 0.02 and OR 1.37 (95% CI 0.94 to 1.99), P = 0.10 for subfertile couples only. When GnRHa and danazol were directly compared, OR was 1.45 (95% CI 1.08 to 1.95) P = 0.01 for all women randomised and OR 1.63( 95% CI 1.12 to 2.37), P = 0.01 for subfertile couples only in favour of GnRH. No effect was observed for GnRH compared with oral contraception; OR 0.99 (95% CI 0.52 to 1.89), P = 0.98 for all women randomised and OR 0.79 ( 95% CI 0.37 to 1.69), P = 0.55. In all analyses the data were statistically homogeneous (I(2)=0%). AUTHORS'
CONCLUSIONS: There is no evidence of benefit in the use of ovulation suppression in subfertile women with endometriosis who wish to conceive.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636607      PMCID: PMC7045467          DOI: 10.1002/14651858.CD000155.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  57 in total

1.  A comparative study of various dosages of danazol in the treatment of endometriosis.

Authors:  R A Low; A D Roberts; D A Lees
Journal:  Br J Obstet Gynaecol       Date:  1984-02

2.  A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis.

Authors:  P Vercellini; P G Crosignani; R Fadini; E Radici; C Belloni; P Sismondi
Journal:  Br J Obstet Gynaecol       Date:  1999-07

3.  Effects of triptorelin versus placebo on the symptoms of endometriosis.

Authors:  A Bergqvist; T Bergh; L Hogström; S Mattsson; F Nordenskjöld; C Rasmussen
Journal:  Fertil Steril       Date:  1998-04       Impact factor: 7.329

4.  Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study.

Authors:  S Bianchi; M Busacca; B Agnoli; M Candiani; C Calia; M Vignali
Journal:  Hum Reprod       Date:  1999-05       Impact factor: 6.918

5.  Elevated serum levels of endometrial secretory protein PP14 in patients with advanced endometriosis. Suppression by treatment with danazol and high-dose medroxyprogesterone acetate.

Authors:  S Telimaa; A Kauppila; L Rönnberg; A M Suikkari; M Seppälä
Journal:  Am J Obstet Gynecol       Date:  1989-10       Impact factor: 8.661

6.  On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol.

Authors:  A M Franssen; P F van der Heijden; C M Thomas; W H Doesburg; W N Willemsen; R Rolland
Journal:  Fertil Steril       Date:  1992-05       Impact factor: 7.329

7.  Medical treatment of endometriosis: a comparative trial.

Authors:  A D Noble; A T Letchworth
Journal:  Postgrad Med J       Date:  1979       Impact factor: 2.401

8.  The importance of laparoscopic coagulation of mild endometriosis in infertile women.

Authors:  K Nowroozi; J S Chase; J H Check; C H Wu
Journal:  Int J Fertil       Date:  1987 Nov-Dec

9.  Gestrinone versus danazol in the treatment of endometriosis.

Authors:  L Fedele; S Bianchi; T Viezzoli; L Arcaini; G B Candiani
Journal:  Fertil Steril       Date:  1989-05       Impact factor: 7.329

10.  A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol.

Authors:  I S Fraser; R P Shearman; R P Jansen; P D Sutherland
Journal:  Aust N Z J Obstet Gynaecol       Date:  1991-05       Impact factor: 2.100

View more
  29 in total

Review 1.  Implantation failure: molecular mechanisms and clinical treatment.

Authors:  Hakan Cakmak; Hugh S Taylor
Journal:  Hum Reprod Update       Date:  2010-08-21       Impact factor: 15.610

Review 2.  Endometriosis and nuclear receptors.

Authors:  Bahar D Yilmaz; Serdar E Bulun
Journal:  Hum Reprod Update       Date:  2019-07-01       Impact factor: 15.610

Review 3.  Endometriosis: an overview of Cochrane Reviews.

Authors:  Julie Brown; Cindy Farquhar
Journal:  Cochrane Database Syst Rev       Date:  2014-03-10

Review 4.  Managing endometriosis-associated infertility.

Authors:  Suneeta Senapati; Kurt Barnhart
Journal:  Clin Obstet Gynecol       Date:  2011-12       Impact factor: 2.190

Review 5.  Clinical practice. Endometriosis.

Authors:  Linda C Giudice
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

Review 6.  Endometriosis and infertility.

Authors:  Carlo Bulletti; Maria Elisabetta Coccia; Silvia Battistoni; Andrea Borini
Journal:  J Assist Reprod Genet       Date:  2010-06-25       Impact factor: 3.412

Review 7.  Clinical management of endometriosis-associated infertility.

Authors:  Yin Mon Khine; Fuminori Taniguchi; Tasuku Harada
Journal:  Reprod Med Biol       Date:  2016-02-17

Review 8.  Gene therapy of benign gynecological diseases.

Authors:  Memy H Hassan; Essam E Othman; Daniela Hornung; Ayman Al-Hendy
Journal:  Adv Drug Deliv Rev       Date:  2009-05-13       Impact factor: 15.470

9.  Bladder endometriosis, a remarkable resemblance in a monozygotic twin.

Authors:  J J van Beek
Journal:  Gynecol Surg       Date:  2009-06-16

Review 10.  Endometriosis: pathogenesis and treatment.

Authors:  Paolo Vercellini; Paola Viganò; Edgardo Somigliana; Luigi Fedele
Journal:  Nat Rev Endocrinol       Date:  2013-12-24       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.